Cel Breast tumors are classified by several grading systems and divided into four main molecular subtypes: Luminal A, Luminal B, Triple negative/basal-like and HER2+. Since luminal A tumors tend to be ER+, their treatment often includes hormonal therapy. HER2+ tumors can be treated with Trastuzumab, an anti-Her2 receptor antibody. Hormonal therapies or Trastuzumab cannot be used for triple negative tumors, which are ER- and HER2-, and these are usually treated with a combination of surgery, radiotherapy and chemotherapy. There is an urgent need for new therapies to effectively treat different breast cancer subtypes. Translating basic knowledge on tumor cell biology into more effective diagnostic tools and improved treatments for patients remains difficult. The use of patient-derived xenografts (PDX) as preclinical models that recapitulate the complexity and heterogeneity of the human tumors should help to develop and successfully translate to the clinic new therapies. Our recent work provides genetic and pharmacological evidence showing that p38 MAPK inhibition cooperates with the chemotherapeutic agent cisplatin to reduce breast tumor size and malignancy in vivo. Our results support a potential therapeutic use for p38 MAPK inhibitors in combination with chemotherapeutic drugs. The idea is to use PDX of specific breast cancer subtypes for preclinical validation of a new drug combination therapy with potential benefit to patients, which can be confirmed in clinical trials. Dziedzina nauki medical and health sciencesclinical medicinesurgerynatural sciencesbiological sciencescell biologymedical and health sciencesclinical medicineoncologybreast cancer Program(-y) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Temat(-y) ERC-PoC-2015 - ERC Proof of Concept Grant Zaproszenie do składania wniosków ERC-2015-PoC Zobacz inne projekty w ramach tego zaproszenia System finansowania ERC-POC - Proof of Concept Grant Instytucja przyjmująca FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) Wkład UE netto € 149 995,00 Adres CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA 08028 Barcelona Hiszpania Zobacz na mapie Region Este Cataluña Barcelona Rodzaj działalności Research Organisations Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 149 995,00 Beneficjenci (1) Sortuj alfabetycznie Sortuj według wkładu UE netto Rozwiń wszystko Zwiń wszystko FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) Hiszpania Wkład UE netto € 149 995,00 Adres CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA 08028 Barcelona Zobacz na mapie Region Este Cataluña Barcelona Rodzaj działalności Research Organisations Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 149 995,00